Coya Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COYA research report →
About the company
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies.
- CEO
- Arun Swaminathan
- IPO
- 2022
- Employees
- 8
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $106.70M
- P/E
- -5.10
- P/S
- 13.44
- P/B
- 2.00
- EV/EBITDA
- -2.65
- Div Yield
- 0.00%
- Gross Margin
- 99.79%
- Op Margin
- -277.02%
- Net Margin
- -266.11%
- ROE
- -57.26%
- ROIC
- -44.23%
- Revenue
- $7.95M · 123.57%
- Net Income
- $-21,226,107 · -42.64%
- EPS
- $-1.27 · -29.59%
- Op Income
- $-20,265,623
- FCF YoY
- -4.38%
- 52W High
- $7.75
- 52W Low
- $3.71
- 50D MA
- $4.75
- 200D MA
- $5.17
- Beta
- 0.51
- Avg Volume
- 173.62K
Get TickerSpark's AI analysis on COYA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 26 | Pavao Mark H | other | 10,000 |
| Apr 1, 26 | Pavao Mark H | other | 0 |
| Jan 22, 26 | SNYDER DAVID S | other | 140,041 |
| Jan 22, 26 | Grossman Fred | other | 140,041 |
| Jan 22, 26 | Berman Howard | other | 15,257 |
| Jan 22, 26 | Swaminathan Arun | other | 293,983 |
| Jan 2, 26 | Villalobos Anabella | other | 10,000 |
| Jan 2, 26 | GOLDSTEIN DOV A MD | other | 10,000 |
| Jan 2, 26 | Weinand Dieter | other | 10,000 |
| Jan 2, 26 | ROSS WILBUR L JR | other | 10,000 |
Our COYA coverage
Recent articles, reports, and earnings notes.
No research on COYA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COYA report →Similar companies
Peers in the same neighborhood.